SynthesisCardiovascular intervention and therapeutics2026
Network meta-analysis of treatment strategies for calcified coronary lesions.
Synthesis in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Risk Stratification in Cardiovascular Medicine for Prognostic Assessment and Therapeutic Decision-Making: From Atrial Fibrillation to the Broader Disease Spectrum.Journal of arrhythmia · 2026Review
- Article
- Novel Hertz Contact Intravascular Lithotripsy: Could We Achieve More in Balloon-Based Calcium Modification?Journal of clinical medicine · 2026Review
- Comparative Performance of Calcium-Modification Strategies for Coronary Lesions: A Network Meta-Analysis of Randomized Trials.Cardiovascular therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comparative evidence on treatment strategies for calcified coronary lesions (CCL) remains scarce, with few head-to-head trials and limited data on clinical outcomes. We conducted a frequentist network meta-analysis of randomized controlled trials (RCTs) comparing excimer laser (ELCA), lithotripsy (IVL), modified balloons (MBA), orbital atherectomy (OA), rotational atherectomy (RA), and RA plus cutting balloons (RA plus CBA) against a conventional strategy (CS). The primary endpoints were severe adverse events (SAE: death, coronary perforation, or slow-flow/no-reflow) and minimum stent area (MSA), while secondary endpoints included major adverse cardiovascular events (MACE) and target lesion revascularization (TLR). Fourteen RCTs including 3,671 patients were analyzed. Atherectomy-based strategies carried a higher risk of SAE versus CS, driven by slow-flow/no-reflow phenomenon. All strategies except OA and ELCA significantly increased MSA compared with CS, with the largest effect observed for RA plus CBA (MD 0.93 mm²; 95% CI 0.48-1.38). None of the strategies reduced MACE or TLR versus CS, although RA plus CBA ranked highest for both endpoints. IVL improved MSA (MD 0.59 mm²; 95% CI 0.14-1.03) without increasing SAE and ranked favorably for MACE and TLR, with the highest probability of lower mortality. Stand-alone MBA remained low-ranked for TLR, and sensitivity analysis confirmed its inferior MSA performance versus IVL. In summary, upfront plaque-modification improved MSA compared with a conventional strategy, although this gain did not translate into significant reductions in MACE or TLR, likely reflecting the limited number of events. RA plus CBA had the highest likelihood of lower MACE and TLR despite higher procedural risk, whereas IVL provided the most favorable balance between safety and efficacy.
Indexed as
Identifiers
41275032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.